NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

Ettinger, David S.; Wood, Douglas E.; Aisner, Dara L.; Akerley, Wallace; Bauman, Jessica R.; Bharat, Ankit; Bruno, Débora S.; Chang, Joe Y.; Chirieac, Lucian R.; D’Amico, Thomas A.; Dilling, Thomas J.; Dowell, Jonathan E.; Gettinger, Scott; Gubens, Matthew A.; Hegde, Aparna; Hennon, Mark; Lackner, Rudy P.; Lanuti, Michael; Leal, Ticiana; Lin, Jules; Loo, Billy W.; Lovly, Christine M.; Martins, Renato; Massarelli, Erminia; Morgensztern, Daniel; Ng, Tony; Otterson, Gregory A.; Patel, Sandip Pravin; Riely, Gregory J.; Schild, Steven E.; Shapiro, Theresa A.; Singh, Aditi; Stevenson, James P.; Tam, Alda L.; Yanagawa, Jane; Yang, Stephen C.; Gregory, Kristina M.; Hughes, Miranda

doi:10.6004/jnccn.2021.0013

Cited by 796 publications

(675 citation statements)

References 55 publications

Supporting

Mentioning

606

Contrasting

Unclassified

Order By: Relevance

“…Alectinib is useful as the first‐line chemotherapy with or without brain metastases because of its higher efficacy and milder adverse events than lorlatinib. Moreover, lorlatinib is recommended as a second‐line treatment for symptomatic ALK‐ positive NSCLC patients with CNS relapse after alectinib [1]. However, in ALK‐ positive NSCLC patients with CNS relapse, carcinomatous meningitis and uncontrollable symptomatic epilepsy cause consciousness disorders.…”

Section: Discussionmentioning

confidence: 99%

“…Based on the appreciable efficacy and mild adverse events, alectinib is useful as the first‐line chemotherapy for patients with anaplastic lymphoma kinase ( ALK ) gene rearrangement‐positive non‐small cell lung cancer ( ALK‐ positive NSCLC) [1]. Lorlatinib or systemic chemotherapy is recommended as a second‐line treatment for patients with symptomatic ALK‐ positive NSCLC exhibiting central nervous system (CNS) relapse upon failure of alectinib treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase‐positive non‐small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report

Sasaki

Yokota

et al. 2021

Respirology Case Reports

View full text Add to dashboard Cite

Alectinib treatment is effective in patients with anaplastic lymphoma kinase (ALK) gene rearrangement‐positive non‐small cell lung cancer (NSCLC; hereafter ALK‐positive NSCLC) who exhibit central nervous system (CNS) relapse and poor performance status (PS). Lorlatinib treatment is effective upon failure of other ALK inhibitor‐based treatments. However, much remains unknown about the efficacy of lorlatinib in patients with ALK‐positive NSCLC, who have triple problems, carcinomatous meningitis, poor PS, and dysphagia, after alectinib treatment. Here, we report the remarkable response of a 73‐year‐old patient with ALK‐positive NSCLC showing carcinomatous meningitis due to CNS metastases, poor PS, and dysphagia to lorlatinib. Lorlatinib administration through a nasogastric tube alleviated complications related to consciousness within three days, and the patient survived for 16 months after CNS relapse. Lorlatinib could be a treatment option for patients with ALK‐positive NSCLC showing carcinomatous meningitis, poor PS, and dysphagia upon failure of other ALK inhibitor‐based treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase‐positive non‐small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report

Sasaki

Yokota

et al. 2021

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

“…In summary, our present study also provided the potential novel target in the investigation through disrupting ANRIL-ATR complex to conquer lung cancer. As indicated in NCCN guideline 2021, radiotherapy and adjuvant chemo-radiotherapy represent important strategies in the treatments of NSCLC [ 16 ]. However, cancer cells usually become to be concomitantly resistant along radiotherapy.…”

Section: Main Textmentioning

confidence: 99%

Long non-coding RNA ANRIL promotes homologous recombination-mediated DNA repair by maintaining ATR protein stability to enhance cancer resistance

Liu

Chen²,

Huang³

et al. 2021

Mol Cancer

View full text Add to dashboard Cite

“…In DestinyLung01 study covering with 42 relapsed/refractory HER2-mutant NSCLC, T-DXd led to a confirmed objective response rate (ORR) of 61.9% and median PFS was 14.0 months (50). FDA already granted a breakthrough therapy designation to T-DXd for the treatment of patients with metastatic HER2-mutant NSCLC (51).…”

Section: Trastuzumab and Its Conjugationmentioning

confidence: 99%

A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers

Wu¹,

Yuan²,

Li³

et al. 2021

J Thorac Dis

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2), as a receptor tyrosine kinase of EGF receptor family, whose mutation is often associated with even if less frequency but poor prognosis and shorter survival in pulmonary malignant tumor. HER2 status include mutation, overexpression, amplification and also some rare genotypes, detected by next generation sequencing (NGS), immunohistochemistry (IHC), and also fluorescence in situ hybridization (FISH). Different genotypes represent different therapeutic targets and indicate different clinical prognosis concluded by previous studies. Unfortunately, no standard guidelines for first-line treatment are widely recognized, and current therapeutic schedules include chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Especially for patients with advanced metastasis, chemotherapy is based as a systemic therapy using studies of breast cancer or EGFR-positive lung adenocarcinoma as a template. Studies already explored treatment including EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and afatinib, and also trastuzumab and its conjugation like HER2-targeted antibodydrug conjugate trastuzumab emtansine (T-DM1) and conjugate trastuzumab deruxtecan (T-DXd). Also, he researches explored combination therapy with chemotherapy and TKIs or monoclonal antibodies. This review describes commonly used therapies for HER2-positive/HER2-overexpression patients and general relationship between genotypes of HER2, drug selection and final prognosis in order to provide suggestions for future diagnosis and treatment.

show abstract

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

Cited by 796 publications

References 55 publications

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase‐positive non‐small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase‐positive non‐small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report

Long non-coding RNA ANRIL promotes homologous recombination-mediated DNA repair by maintaining ATR protein stability to enhance cancer resistance

A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers

Contact Info

Product

Resources

About